Focused On-demand Library for Ephrin type-A receptor 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P29320

UPID:

EPHA3_HUMAN

Alternative names:

EPH-like kinase 4; HEK; Tyrosine-protein kinase TYRO4; Tyrosine-protein kinase receptor ETK1

Alternative UPACC:

P29320; Q9H2V3; Q9H2V4

Background:

Ephrin type-A receptor 3, known by alternative names such as EPH-like kinase 4 and Tyrosine-protein kinase receptor ETK1, plays a pivotal role in various cellular processes. This receptor tyrosine kinase engages in bidirectional signaling by binding with ephrin family ligands, influencing cell-cell adhesion, cytoskeletal organization, and cell migration. It is crucial in cardiac development, retinotectal mapping, and neuromuscular circuit formation.

Therapeutic significance:

Given its involvement in colorectal cancer, characterized by malignant lesions in the colon and rectum, Ephrin type-A receptor 3 presents a promising target for therapeutic intervention. Understanding its role could open doors to novel strategies for managing this complex disease.